Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.

Florence Kurth

Florenz Sartorius

Sartorius Aktiengesellschaft

Amgen Bangladesh is a subsidiary of Amgen Inc., one of the world's leading biotechnology companies. The company is dedicated to discovering, developing, manufacturing, and delivering innovative human therapeutics. It focuses on areas of high unmet medical need, leveraging expertise in biology, chemical engineering, and a variety of other scientific disciplines to develop medicines that can help millions of patients around the world.

George Rathmann

Amgen Bangladesh

BioGenerator Ventures creates, builds, and invests in companies that are solving important problems in human health and agriculture.

BioGenerator Ventures

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.

Ingmar Hoerr

Steve Pascolo

Florian von der Mulbe

CureVac N.V.

Sartorius provides technologies and services for the biopharmaceutical industry and life sciences research. It offers products and solutions related to bioprocessing, laboratory equipment, and analytics.

Sartorius

iQue® High-Throughput Screening (HTS) by Cytometry

Lab Essentials for Research and Development

Octet®- Affinity, Binding Kinetics and Concentration

Incucyte® - Live-Cell Analysis Systems

Sartorius Food & Beverage

Lab Essentials for Quality Control

CellCelector - Single Cell, Colony or Organoid Selection and Retrieval

Sartorius Stedim Biotech

Sartorius is a leading international partner of life sciences research and biopharmaceutical manufacturing. 

We help our customers #SimplifyProgress from drug discovery to manufacturing so that more people can have access to better medicine. With this, we are #PartOfTheSolution in the fight against diseases worldwide.

With innovative laboratory instruments and consumables, the our Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. 

The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and economically. 

Based in Göttingen, Germany, Sartorius also has a strong global reach with around 60 production and sales sites worldwide. We regularly expand our portfolio through the acquisition of complementary technologies. 

In 2023, Sartorius generated sales revenue of around 3.4 billion euros. Currently, around 14,600 employees from around 110 nations are working for customers around the globe.

Join our team, partner or collaborate with us.

Green sustainability at Sartorius' headquarters 🍃

Did you know that the Earth itself can power buildings? At the Sartorius Campus in Göttingen, Germany, we're doing just that! 

With the largest geothermal probe field in Lower Saxony, we harness the Earth's natural temperature to heat and cool three buildings.☀️❄️ This approach is a great leap towards our goal of zero avoidable emissions in Scope 1 and 2 by 2030. 

Curious to learn more about how this project contributes to our sustainability goals? 
➡️ Dive into our latest blog post: https://ow.ly/hJT450TlGGS

#Sustainability #GeothermalEnergy #SimplifyingProgress

Empowerment in Focus: Sartorius Business Women Association Day 2024 🌟 

Yesterday, the Sartorius Business Women Association (SBWA) brought together a powerhouse of ambitious women at the "Meet the SBWA Day" event, held both onsite at Campus Göttingen and virtually. 🤝 

The event featured a standout panel discussion on empowering women in leadership, led by Alexandra Gatzemeyer, Executive Board Member and Head of Lab Products & Services, and Michaela Pischke, Head of Business Area Separation Technologies. They shared personal career stories, insightful advice on leadership, and practical tips for navigating career growth while balancing life’s demands. 👩‍💼✨ 

🔑 Key takeaway from Alexandra: “When you're young, it can be challenging to determine the direction of your career. My advice is to experiment and explore – whether it's a different role, a new function, or even another region. Be open and communicate your career ambitions clearly.“ 

🔑 Key takeaway from Michaela: “Don’t be afraid to make mistakes. It’s part of the journey and they help you learn and grow further.” 

Here's to creating more opportunities for women to rise, lead, and thrive! 💪  

Find out more about women at Sartorius: https://ow.ly/J9aa50TjHVr 

#Empowerment #WomenInLeadership #SBWA #Networking #CareerGrowth #Sartorius

Der niedersächsische Ministerpräsident Stephan Weil war heute zu Besuch auf unserem Campus in Göttingen, um sich über die Förderung von Talenten und Innovationen bei Sartorius zu informieren. Begleitet wurde Weil von der Bundestagsabgeordneten Frauke Heiligenstadt, dem Landtagsabgeordneten Gerd Hujahn und Göttingens Oberbürgermeisterin Petra Broistedt.

Die Delegation besichtigte das Testlabor im neuen Forschungs- und Entwicklungsgebäude, wo ihr die Funktionsweise von Bioreaktoren demonstriert wurde, die bei der Erforschung und Herstellung von biopharmazeutischen Medikamenten eingesetzt werden. Im Anschluss tauschte sich die Gruppe bei einem gemeinsamen Mittagessen mit #MINT Talenten aus, die bei Sartorius eine Ausbildung oder ein duales Studium absolvieren.

Bereits am Dienstag hatten Weil, Kreuzburg und weitere Akteure aus Südniedersachsen eine Erklärung zur Gründung des "Life Science Valley Niedersachsen" unterzeichnet. Mit der Initiative soll die Region zu einem führenden Life-Science-Standort und Gründungszentrum in Deutschland entwickelt werden.

🤝 Land Niedersachsen Life Science Valley 

#SimplifyingProgress #LifeSciences #Niedersachsen

Managers have an essential role at every company. It is up to their qualities as leaders to create a collaborative, supporting and rewarding work atmosphere for people to grow and make a contribution. 🤝

At Sartorius, they are especially called upon to lead our teams towards achieving our vision as a company: Better health for more people.

Already in 2007, we put into writing what good leadership means to us. These principles remain up to date even more today as a global corporation with around 14,000 employees at more than 60 sites. 

Browse the Sartorius Leadership Guidelines to learn more. 

Do you share these ideals? ➡️ Check out https://ow.ly/FwVm50T2Ojv and find your next management role. 

#Leadership #Leadershipmindset #Management

🌍 Job Application Tips from Around the World 🌍 

Sartorius currently offers 40+ open positions in India. Are you looking for a new challenge in IT, Operations, Services, Sales, R&D or Quality? 🔎 

Gain insights from Koshel S., our Manager of Talent Acquisition for the Asia/Pacific region, on the job application process in India. Discover the best way to present yourself and learn more about what to emphasize in your interview and why a professional network is important. 💡 

➡️ Read the full interview on the Sartorius blog: https://sar.to/0an98

#Careers #JobApplication #LifeSciences #Biopharma

Sartorius is dedicated to providing an open, trustful and collaborative working atmosphere 🤝where our people can succeed in supporting our customers to develop new drugs. 

It lies in the hands of our managers to actively establish and maintain the accompanying standards and culture in their team as well as to promote everyone’s personal and professional development.

Dig deeper into our Leadership Guidelines and learn more about the principle of “Active Leadership” ➡️www.sartorius.com/careers

#leadership #leadershipmindset #management

Metric
Company Name	Sartorius Aktiengesellschaft	Amgen Bangladesh	BioGenerator Ventures	CureVac N.V.
Symbol	SRT			CVAC
MSH ID	COM:SARTORIUS	COM:AMGENBD	COM:BIOGENERATORVENTURES	COM:CUREVAC
Market	STOCKS	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare	Healthcare & Health Services	Financial Services & Finance	Healthcare
Industry	Medical - Instruments & Supplies	Biotechnology	Venture Capital	Biotechnology
Country	DE		US	DE
Stage
Employee Count	14.61K	10.00K	36	999
Website	sartorius.com	amgenbd.com	biogeneratorventures.com	curevac.com
LinkedIn	sartorius		biogeneratorventures	curevac
Founders

Metric
Market Cap	15.56B		697.59M
Enterprise Value
Monthly Web Traffic	1.07M	1.21K
Web Traffic Growth	1.47	-0.18
Valuation
Raised Capital

Metric
Revenue	3.59B	55.66M
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.66B	-283.68M
EBITDA	890.51M	-283.68M
Operating Income	528.96M	-283.68M
Net Income	357.53M
EPS	5.23
Diluted EPS	5.23
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.46	-1.45
Operating Profit Margin	0.16	-4.47
EBITDA Margin	0.25	-5.10
Net Profit Margin	0.09	-4.23
Return on Equity	0.15	-0.42
Return on Assets	0.03	-0.33
Return on Capital Employed	0.07	-0.44

COM:SARTORIUS

Sartorius

Last Close

175.80

25/11 08:16

Market Cap

14.73B

Beta: -

Volume Today

837

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	41.01	-2.40
P/B Ratio	8.67	1.20
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	6.48	17.59
EV Multiple	19.08	-2.91

Metric
Days Sales Outstanding	42.10	185.14
Days Payables Outstanding	91.49	30.43
Days Inventory Outstanding	206.95	69.41
Operating Cycle	260.52	315.95
Cash Conversion Cycle	181.83	256.90
Asset Turnover	0.35	0.12

Metric
Operating Cash Flow	901.60M	-277.15M
Free Cash Flow	310.43M	-334.26M
Cash Flow to Debt	0.18	-6.32
Operating Cash Flow/Sales	0.25	-4.37
Free Cash Flow Yield	0.01	-0.46

Metric
Cash & Equivalents	400.52M	425.43M
Accounts Receivable	178.08M	-8.36M
Inventory	1.10B	26.22M
Goodwill	3.61B	13.17M
Debt to Capitalization	0.72	0.09
Debt to Assets	0.54	0.05
Current Ratio	1.49	3.56
Quick Ratio	1.19	3.25

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.21
R&D to Revenue	0.05	2.56
SG&A to Revenue	0.05	1.82